SCHEMBL6821458

SCHEMBL6821458

CC(C)n1nc(-c2c(-c3ccccc3)nn3ccc(Oc4ccncc4)cc23)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.39
MAPK14 Q16539 2/20 0.36
IGF1R P08069 1/20 0.35
ADORA2A P29274 2/20 0.33
EGFR P00533 1/20 0.33
RAF1 P04049 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2B P29275 1/20 0.33
GSK3B P49841 1/20 0.33
MAPK1 P28482 2/20 0.32
FAAH O00519 1/20 0.32
BMPR1B O00238 1/20 0.32
BMPR1A P36894 1/20 0.32
TGFBR1 P36897 1/20 0.32
ACVRL1 P37023 1/20 0.32
ACVR1 Q04771 1/20 0.32
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822033 0.94 ADORA1 (0.41) ADORA1MAPK14IGF1RMAPK1FAAH
SCHEMBL6818404 0.87 SRC (0.40) ADORA1MAPK14ADORA2AEGFRRAF1
SCHEMBL6821959 0.87 ADORA1 (0.42) ADORA1IGF1REGFRMAPK1PDE1A
SCHEMBL6821484 0.87 ADORA1 (0.38) ADORA1MAPK14IGF1RMAPK1CMKLR1
SCHEMBL6822257 0.86 ADORA1 (0.43) ADORA1IGF1RMAPK1PDE1APDE1B
SCHEMBL6822058 0.85 ADORA1 (0.42) ADORA1IGF1RADORA2AEGFRPOLB
SCHEMBL6818467 0.84 DRD1 (0.37) ADORA1GSK3B
SCHEMBL6822546 0.83 ADORA1 (0.41) ADORA1IGF1REGFRCMKLR1
SCHEMBL6822608 0.83 CMKLR1 (0.41) ADORA1MAPK14CMKLR1
SCHEMBL6818462 0.83 GSK3B (0.36) ADORA1GSK3BFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885MAPK14 3737/4885IGF1R 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.